Press Releases

Year

March 15, 2021

Beam Therapeutics Announces Business and Pipeline Progress and Reports Fourth Quarter and Full Year 2020 Financial Results

Company On-track to Submit First IND with BEAM-101 in the Second Half of 2021 Acquisition of Guide Therapeutics Supports Targeting of Diverse Tissues for In Vivo Delivery of Gene Editing Team Bolstered by Appointment of Amy Simon, M.D., as Chief Medical Officer and Kate Walsh to Board of Directors

March 15, 2021

Beam Therapeutics Appoints Amy Simon, M.D., Chief Medical Officer

CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that drug development expert Amy Simon, M.D., has been appointed as the company’s chief medical officer.

March 4, 2021

Beam Therapeutics to Participate in the Barclays 2021 Global Healthcare Conference

CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the Barclays 2021

February 23, 2021

Beam Therapeutics Announces Acquisition of Guide Therapeutics

GuideTx’s Proprietary LNP Screening Technology and Lipid Library Supports Expanded Targeting of Diverse Tissues for In Vivo Delivery of Gene Editing CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic

January 19, 2021

Beam Therapeutics Inc. Announces $260 Million Common Stock Investment from Multiple Investors

CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM) (the “Company”), a biotechnology company developing precision genetic medicines through base editing, today announced that it has agreed to sell 2,795,700 shares of its common stock to certain institutional

January 11, 2021

Beam Therapeutics Appoints Leading Healthcare Executive Kate Walsh to its Board of Directors

CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Kate Walsh, president and chief executive officer of the Boston Medical Center (BMC) health system,

January 5, 2021

Beam Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will present at the 39 th Annual J.P.

Investor Center

Investors & Media

Stockholder Tools

Press Releases

Press Releases

Investors & Media

Stockholder Tools